ARE YOU A SUBSCRIBER? LOG IN HERE TO ACCESS FULL ISSUES AND ARTICLES
OCTOBER 16, 2017 ANNOUNCEMENT: INDIVIDUAL ARTICLE ACCESS NOW AVAILABLE FOR OUR SUBSCRIBERS: Ask Us for Details!
ALSO SEE: Updated Coverage by Topic Page
Table of Contents – The MedTech Strategist, Vol. 4, No. 14, October 12, 2017 (48 Pages; Purchase This Full Issue):
- In Memoriam—“Ray Williams: CV’s Founding Father,” by David Cassak
- Diabetes Market Update—“Diabetes Devices: A Market in Transition,” by Mary Thompson
- CEO Perspectives—“The View from the Trenches: CEOs’ Do’s and Don’ts for Running a Company,” by Stephen Levin
- Artificial Intelligence—“Analytics 4 Life: Using AI to Diagnose Coronary Artery Disease at the Point-of-Care,” by Mary Stuart
- Group Purchasing—“Time for Medtechs to Rethink GPOs?” by Ken Graves, Kevin Grabenstatter and Jonas Funk, LEK Consulting
- Start-Ups To Watch—“Allotrope Medical: A Simple Solution for Protecting the Ureter During Surgery,” by Mary Stuart
Ray Williams: CV’s Founding Father
By David Cassak
Ray Williams, who passed away this summer, was a seminal figure in interventional cardiology, a founder and investor in companies from Advanced Cardiovascular Systems to Target Therapeutics, Ventritex to DVI. Other serial entrepreneurs may be better known, but no one had the kind of influence and impact on the cardiovascular device industry that Williams did.
Abbott—Becton Dickinson & Co.—Eli Lilly & Co.—Medtronic plc—Pfizer Inc.—Philips Medical Systems—SurgeRx Medical—Zoll Medical Corp.
Diabetes Market Update
Diabetes Devices: A Market in Transition
By Mary Thompson
The diabetes device arena is has seen a number of new product approvals and launches recently, some of which have the potential to dramatically change the patient care paradigm. Two new devices in particular have attracted substantial attention: Medtronic’s 670G, the first artificial pancreas (AP) system to reach commercialization, now in limited launch in the US; and Abbott’s newly FDA-approved FreeStyle Libre Flash glucose monitoring system, a low-cost, on-demand wearable glucose sensor system that could upend the continuous glucose monitoring market.
Abbott—Apple-Beta Bionics—Bigfoot Biomedical—Dexcom—Eli Lilly & Co.—Fitbit—Glooko—Glysens—Hygieia—IBM Watson—Integrity Applications—Johnson & Johnson—Medtronic plc—Novo Nordisk—Roche Diabetes Care—Senseonics—Tandem Diabetes Care—TypeZero Technologies—Valeritas
The View from the Trenches: CEOs’ Do’s and Don’ts for Running a Company
By Stephen Levin
Four experienced medtech CEOs/entrepreneurs share the challenges and successes they have faced heading companies in the current corporate climate. Lesson #1: You learn more from your losses than from your wins.
Abbott—FIRE1—Medtronic plc—Quanta Dialysis Technologies—ResMed Inc.—Stentys SA
Analytics 4 Life: Using AI to Diagnose Coronary Artery Disease at the Point-of-Care
By Mary Stuart
Analytics 4 Life has been stealthy until recently, but on the eve of the completion of its clinical trial has unveiled a new modality that uses AI to measure disease, one that makes sense of electrical signals that can be measured non-invasively. The company’s target application—coronary artery disease—checks off all the boxes of qualities required for the success of a disruptive and valuable application of AI, including a large clinical need, and a machine-learning application that can be trained by a sufficient volume of high quality input and outcomes data. If successful, the company will improve the efficacy, efficiency, and economics of CAD diagnosis.
Analytics 4 Life—GE Healthcare—Johnson & Johnson—Medtronic plc—Synaptive Medical
Time for Medtechs to Rethink GPOs?
By Ken Graves, Kevin Grabenstatter, and Jonas Funk, LEK Consulting
Medtech companies have long had a complicated relationship with group purchasing organizations (GPOs), especially with the national GPOs. GPOs offer opportunity for greater market coverage and efficient contracting, both of which benefit medtechs and their provider customers. At the same time, there has always been pervasive and not-so-subtle grumbling about the market influence that GPOs can wield and the level of reciprocal value realized by medtech companies. However, relationships are changing between health systems and their GPOs, and the GPO landscape itself is rapidly evolving, offering an opportunity for medtech companies to revisit and reshape their own relationships with GPOs.
Amazon—AVIA Innovator Network—GE Healthcare—HealthTrust Purchasing Group LP—Intalere—Medtronic plc—OpenMarkets—Philips Medical—Premier Inc.—Vizient Inc.
Start-Ups To Watch
Allotrope Medical: A Simple Solution for Protecting the Ureter During Surgery
By Mary Stuart
There are 3 million surgical procedures each year in the US in which there is a risk of injuring the ureter, and rates of injury are highest in minimally-invasive cases, where up to 30% of OR time can be spent on trying to identify the ureter to spare it from harm. Allotrope Medical has developed an intuitive, battery-operated, single-use handheld device to help surgeons see the location of this hidden part of the anatomy.